Literature DB >> 14623772

EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.

Marcel W Bekkenk, Maarten H Vermeer, Chris J L M Meijer, Patty M Jansen, Jaap M Middeldorp, Servi J C Stevens, Rein Willemze.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14623772     DOI： 10.1182/blood-2003-07-2436

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.

Authors:  Junko Yamaguchi; Takahiro Fujino; Reiko Isa; Daichi Nishiyama; Saeko Kuwahara-Ota; Yuka Kawaji; Taku Tsukamoto; Yoshiaki Chinen; Yuji Shimura; Tsutomu Kobayashi; Shigeo Horiike; Kei Kohno; Shigeo Nakamura; Junya Kuroda
Journal:  Haematologica       Date:  2019-04-11       Impact factor: 9.941

2.  T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.

Authors:  Mareike Verbeek; Falko Fend; Thomas Licht; Christian Meyer zum Büschenfelde; Jens Stollfuss; Christian Peschel; Justus Duyster
Journal:  Nat Rev Clin Oncol       Date:  2010-02       Impact factor: 66.675

Review 3.  Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.

Authors:  Bettina M Knoll; K Seiter
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553

4.  Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.

Authors:  Massimo Breccia; Corrado Girmenia; Roberto Latagliata; Giuseppina Loglisci; Michelina Santopietro; Vincenzo Federico; Luigi Petrucci; Alessandra Serrao; Adriano Salaroli; Giuliana Alimena
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-16       Impact factor: 2.576

5.  Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib.

Authors:  Tianxiang Lei; Fengbo Tan; Zhouhua Hou; Peng Liu; Xianhui Zhao; Heli Liu
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244

6.  Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.

Authors:  Hemant Kulkarni; Harald H H Göring; Vincent Diego; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless
Journal:  BMC Med Genomics       Date:  2012-08-23       Impact factor: 3.063
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.